MHP
SCPH

Manatuck Hill Partners’s scPharmaceuticals SCPH Stock Holding History

Manatuck Hill Partners’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-91,200
Closed -$572K – 141
2023
Q4 		$572K Buy
+91,200
New +$522K 0.24% 88

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $24.4B AUM 22.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

Manatuck Hill Partners's SCPH Position: Q1 2024 in Review

Manatuck Hill Partners sold out of scPharmaceuticals (SCPH) in Q1 2024, closing a stake of 91,200 shares — an estimated $572K sold.

Manatuck Hill Partners first reported a position in SCPH in Q4 2023 and held it in 1 quarter. The position peaked at $572K in Q4 2023. 76 funds tracked by Wall St. Rank hold SCPH as of Q1 2024.

  • Manatuck Hill Partners reported no remaining scPharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Manatuck Hill Partners sold 91,200 scPharmaceuticals shares in Q1 2024, an estimated $572K.
  • Manatuck Hill Partners first reported a position in scPharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Manatuck Hill Partners's scPharmaceuticals position peaked at $572K in Q4 2023.
  • 76 funds tracked by Wall St. Rank held scPharmaceuticals as of Q1 2024.

Based on Manatuck Hill Partners's 13F filing for Q1 2024, filed 15 May 2024.